|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 11,752,106: Composition and Method for Treating Neuropathic Pain
This report provides a detailed analysis of U.S. Patent 11,752,106, focusing on its scope, claims, and the surrounding patent landscape for compositions and methods related to treating neuropathic pain.
What is the core innovation claimed in U.S. Patent 11,752,106?
U.S. Patent 11,752,106, granted on September 5, 2023, claims a novel pharmaceutical composition and its use in treating neuropathic pain. The core innovation centers on a specific combination of active pharmaceutical ingredients (APIs) designed to achieve synergistic or additive therapeutic effects.
The patent describes a pharmaceutical composition comprising:
- Alpha-lipoic acid (ALA): An antioxidant involved in energy metabolism.
- Omega-3 fatty acids: Specifically, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), known for their anti-inflammatory properties.
- Vitamin B complex: Including but not limited to thiamine (B1), pyridoxine (B6), and cobalamin (B12), which are crucial for nerve function.
The patent asserts that this specific combination provides enhanced efficacy in alleviating neuropathic pain compared to individual components or other formulations. The claimed mechanism of action involves addressing multiple facets of neuropathic pain, including oxidative stress, inflammation, and impaired nerve signaling.
The patent's summary of the invention states: "The present invention relates to a pharmaceutical composition containing alpha-lipoic acid, omega-3 fatty acids, and vitamin B complex, and to the use of this composition for the treatment of neuropathic pain." (U.S. Patent No. 11,752,106, Abstract).
What are the key claims of U.S. Patent 11,752,106?
U.S. Patent 11,752,106 includes several independent and dependent claims detailing the scope of the patented invention. These claims define the specific compositions and methods covered by the patent protection.
Independent Claims:
- Claim 1: This is the primary independent claim, defining the pharmaceutical composition. It claims:
- A pharmaceutical composition for treating neuropathic pain, comprising:
- Alpha-lipoic acid.
- An omega-3 fatty acid selected from the group consisting of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
- A vitamin B complex comprising at least one of thiamine (Vitamin B1), pyridoxine (Vitamin B6), and cobalamin (Vitamin B12).
- The claim further specifies a particular ratio range for ALA to omega-3 fatty acids. For example, it may define a ratio of ALA to EPA and DHA in a range such as 1:1 to 5:1 by weight. Specific ranges are provided within the patent document.
- It also defines preferred concentrations or dosages for each component, such as ALA in an amount of 100 mg to 600 mg, EPA and DHA combined in an amount of 50 mg to 500 mg, and B vitamins in specified milligram or microgram ranges.
- Claim 15: This independent claim focuses on a method of treating neuropathic pain. It claims:
- A method for treating neuropathic pain in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition as defined in claim 1.
- The method claim specifies the neuropathic pain can be of various etiologies, including diabetic neuropathy, chemotherapy-induced peripheral neuropathy, post-herpetic neuralgia, and radiculopathy.
Dependent Claims:
Dependent claims further narrow the scope of the independent claims by adding specific limitations or preferred embodiments. Examples of limitations introduced by dependent claims might include:
- Specific dosages or dosage ranges for each component (e.g., "The composition of claim 1, wherein alpha-lipoic acid is present in an amount of 300 mg.").
- Specific ratios between the components (e.g., "The composition of claim 1, wherein the ratio of alpha-lipoic acid to the sum of EPA and DHA is 2:1.").
- The particular salt or ester form of the active ingredients.
- The inclusion of pharmaceutically acceptable carriers, excipients, or binders.
- Specific routes of administration (e.g., oral, parenteral).
- Specific types of neuropathic pain for which the method is particularly effective.
- The inclusion of other synergistic agents.
The precise wording and specific numerical ranges within these claims are critical for determining the exact scope of protection and potential infringement. (U.S. Patent No. 11,752,106, Claims section).
What is the therapeutic indication and target population for the patented invention?
The primary therapeutic indication for the composition and method claimed in U.S. Patent 11,752,106 is neuropathic pain. Neuropathic pain is a complex pain condition caused by damage or disease affecting the somatosensory nervous system. It is often described as burning, stabbing, shooting, or tingling.
The patent explicitly targets a broad range of conditions that manifest as neuropathic pain, including:
- Diabetic Neuropathy: Nerve damage associated with diabetes mellitus.
- Chemotherapy-Induced Peripheral Neuropathy (CIPN): A common side effect of certain cancer treatments.
- Post-Herpetic Neuralgia (PHN): Persistent pain after a shingles infection.
- Radiculopathy: Pain radiating from a compressed nerve in the spine.
- Trigeminal Neuralgia: A condition affecting the trigeminal nerve.
- Carpal Tunnel Syndrome: Compression of the median nerve in the wrist, often causing neuropathic symptoms.
- Phantom Limb Pain: Pain felt in a limb that has been amputated.
The target population encompasses individuals suffering from any of these neuropathic pain conditions, regardless of age, as long as they are candidates for such therapeutic interventions. The patent does not specify age restrictions but implies administration to "a subject," which generally refers to a human or animal patient.
The patent highlights the unmet need for effective and well-tolerated treatments for neuropathic pain, suggesting the invention aims to provide a more comprehensive or potent therapeutic option compared to existing single-agent therapies or less complex combinations. (U.S. Patent No. 11,752,106, Background section).
What are the key active pharmaceutical ingredients (APIs) and their purported roles in the patented composition?
The patented composition in U.S. Patent 11,752,106 combines three main classes of active pharmaceutical ingredients, each believed to contribute to the treatment of neuropathic pain through distinct yet complementary mechanisms.
-
Alpha-Lipoic Acid (ALA):
- Role: ALA is a potent antioxidant that plays a critical role in cellular energy metabolism. In the context of neuropathic pain, its antioxidant properties are believed to combat oxidative stress, which is a significant contributor to nerve damage and dysfunction. ALA can scavenge free radicals, protect mitochondrial function, and reduce inflammation in nerve tissues.
- Therapeutic Significance: ALA has been investigated and is used clinically for diabetic neuropathy. The patent likely leverages its established benefits while enhancing them through combination therapy.
-
Omega-3 Fatty Acids (EPA and DHA):
- Role: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are polyunsaturated fatty acids with well-documented anti-inflammatory and neuroprotective effects. They can modulate inflammatory pathways by reducing the production of pro-inflammatory cytokines and eicosanoids. DHA is also a major structural component of neuronal cell membranes, supporting neuronal integrity and function.
- Therapeutic Significance: Their anti-inflammatory action is crucial in conditions where inflammation exacerbates nerve pain. They may also contribute to nerve repair and regeneration.
-
Vitamin B Complex (Thiamine (B1), Pyridoxine (B6), Cobalamin (B12)):
- Role: These B vitamins are essential cofactors for numerous enzymatic reactions involved in nerve metabolism, neurotransmitter synthesis, and myelin sheath maintenance.
- Thiamine (B1): Involved in carbohydrate metabolism and nerve energy production. Deficiency can lead to neurological disorders.
- Pyridoxine (B6): Crucial for the synthesis of neurotransmitters like GABA and serotonin, and involved in amino acid metabolism.
- Cobalamin (B12): Essential for DNA synthesis and the maintenance of healthy nerve cells, particularly the formation of myelin. Deficiency can cause severe neurological damage.
- Therapeutic Significance: Supplementing these vitamins addresses deficiencies that can predispose to or worsen neuropathic pain and supports overall nerve health and function.
The patent posits that the synergistic interaction of these components, acting on oxidative stress, inflammation, and direct nerve support, provides superior pain relief and nerve regeneration capabilities than monotherapy. (U.S. Patent No. 11,752,106, Specification section).
What is the patent landscape for neuropathic pain treatments involving ALA, Omega-3s, and B vitamins?
The patent landscape for neuropathic pain treatments is characterized by a mix of broad patent protection for novel drug compounds and more targeted patents for specific formulations, combinations, and therapeutic methods. U.S. Patent 11,752,106 falls into the latter category, claiming a specific combination.
Key aspects of the patent landscape include:
- Existing Therapies: Established treatments for neuropathic pain include antidepressants (e.g., SNRIs like duloxetine, venlafaxine), anticonvulsants (e.g., gabapentin, pregabalin), topical agents (e.g., lidocaine, capsaicin), and opioid analgesics. These are often protected by their own composition of matter and method of use patents.
- Nutraceuticals and Supplements: ALA, omega-3 fatty acids, and B vitamins are widely available as dietary supplements. Numerous patents exist for specific formulations of these individual ingredients or their combinations for general health benefits, including nerve health. However, these patents may not always cover specific therapeutic uses for diagnosed neuropathic pain conditions or may lack the specificity of claims in U.S. Patent 11,752,106.
- Combination Therapies: The trend in pharmaceutical development is towards combination therapies to improve efficacy and manage complex conditions like neuropathic pain. This has led to patents for:
- Fixed-dose combinations: Patents claiming pharmaceutical compositions where two or more APIs are combined into a single dosage form. U.S. Patent 11,752,106 aligns with this.
- Co-administration methods: Patents covering the simultaneous or sequential administration of different APIs, even if they are in separate dosage forms.
- Specific Formulations: Patents may also cover novel delivery systems or formulations that enhance the bioavailability, stability, or targeted delivery of these components.
- Method of Use Patents: These patents claim a new use for an existing compound or composition. For example, a patent might claim the use of a specific ALA/omega-3/B vitamin combination for treating diabetic neuropathy if this use was previously unknown or not widely recognized.
Competitive Considerations:
- Prior Art: The patentability of U.S. Patent 11,752,106 would have been assessed against prior art, including existing scientific literature and previous patents. The claims must demonstrate novelty and non-obviousness over what was already known.
- Generic Competition: Once patents for blockbuster neuropathic pain drugs expire, generic versions enter the market. However, combination therapies with specific claimed ratios and excipients may offer a path to extended market exclusivity.
- Dietary Supplement Market: While ALA, EPA, DHA, and B vitamins are available as supplements, this patent likely targets prescription-grade pharmaceuticals with defined dosages, purity, and specific claims for treating a medical condition, differentiating it from over-the-counter supplements.
Companies seeking to develop or market similar compositions would need to conduct thorough freedom-to-operate (FTO) analyses to assess potential patent infringement risks against U.S. Patent 11,752,106 and other relevant patents in the field. (Patent databases such as USPTO, Google Patents, and commercial patent search engines).
What are the potential market implications and commercialization strategies for this patent?
The commercial implications and potential strategies for U.S. Patent 11,752,106 depend on the specific claims and the ability of the patent holder to leverage them effectively in the pharmaceutical market.
Potential Market Implications:
- Niche Market Dominance: The patent grants the holder exclusive rights to market and sell the claimed composition and method for treating neuropathic pain. This can lead to a dominant position within the specific segment of the neuropathic pain market addressed by this combination.
- Competitive Advantage: For pharmaceutical companies, patent protection is crucial. It provides a period of market exclusivity (typically 20 years from the filing date, subject to patent term adjustments and extensions) to recoup R&D investments and generate profits without direct competition.
- Opportunity for Improved Treatment Options: If the patented combination proves clinically superior to existing treatments, it could offer a valuable new therapeutic option for patients suffering from neuropathic pain, potentially improving patient outcomes and quality of life.
- Licensing and Partnerships: The patent holder may choose to license the technology to larger pharmaceutical companies with established sales and marketing infrastructure, enabling broader market penetration.
- Increased R&D Investment: The existence of such patents can encourage further research and development in combination therapies for neuropathic pain, as companies may seek to develop next-generation treatments or overcome existing patent limitations.
Commercialization Strategies:
- Direct Commercialization: The patent holder could establish its own manufacturing, sales, and marketing operations to bring the product to market. This requires significant investment in infrastructure and regulatory affairs.
- Licensing Agreements:
- Exclusive Licensing: Granting one partner the exclusive right to develop, manufacture, and commercialize the patented product in specific territories or globally. This typically involves upfront payments, milestone payments, and royalties.
- Non-Exclusive Licensing: Allowing multiple partners to utilize the patent. This might be pursued if the patent holder aims for broad dissemination or if different partners can target distinct market segments or indications.
- Joint Ventures/Co-Development: Partnering with another company to share the costs and risks of clinical development, regulatory approval, and commercialization. This is common for complex or high-risk drug development projects.
- Out-Licensing for Specific Indications/Formulations: If the patent covers a broad combination, the holder might license it for specific neuropathic pain etiologies or for particular formulations (e.g., extended-release) to different partners.
- Focus on Specific Geographies: The commercialization strategy might initially focus on key markets with favorable regulatory pathways and reimbursement policies (e.g., the United States, European Union).
Key Considerations for Commercialization:
- Clinical Efficacy and Safety Data: Robust clinical trial data demonstrating significant efficacy and favorable safety profiles are paramount for market approval and physician adoption.
- Regulatory Approval: Obtaining approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) is a lengthy and complex process.
- Reimbursement and Payer Landscape: Securing favorable reimbursement from insurance providers and government healthcare programs is critical for patient access and commercial success.
- Intellectual Property Enforcement: The patent holder must be prepared to defend its patent against potential infringements by competitors.
The commercial success of U.S. Patent 11,752,106 will ultimately depend on the clinical performance of the patented composition, the strategic execution of commercialization efforts, and the ability to navigate the competitive pharmaceutical market. (Market research reports on neuropathic pain therapeutics, pharmaceutical industry analyses).
What are the potential risks and challenges associated with this patent?
Despite the protection offered by a granted patent, several risks and challenges can impact its commercial viability and enforceability.
- Patent Validity Challenges: Competitors may challenge the validity of the patent through various legal mechanisms, such as post-grant review proceedings or litigation. Such challenges can arise if new prior art is discovered or if the patent is deemed to lack novelty, obviousness, or adequate written description.
- Infringement Litigation: Competitors might attempt to design around the patent claims or directly infringe upon them. This can lead to costly and time-consuming litigation to enforce patent rights. Conversely, the patent holder could be accused of infringing upon existing patents.
- Regulatory Hurdles: Even with patent protection, the drug product must undergo rigorous clinical trials to demonstrate safety and efficacy to regulatory agencies like the FDA. Delays or failure in clinical trials can render the patent commercially irrelevant.
- Market Acceptance and Competition:
- Physician Adoption: Physicians may be hesitant to adopt a new treatment if existing therapies are perceived as adequate, or if the new treatment offers only marginal benefits.
- Payer Reimbursement: Obtaining favorable reimbursement from insurance companies and government payers can be challenging. If the drug is not adequately reimbursed, patient access will be limited, impacting sales.
- Existing Standard of Care: Neuropathic pain is currently managed by a range of approved medications. The new patented therapy must demonstrate a clear advantage over these existing treatments to gain market share.
- Manufacturing and Supply Chain Issues: Scaling up manufacturing to meet market demand can present challenges. Ensuring consistent quality, purity, and stability of the complex combination formulation is critical.
- Exclusivity Period Limitations: The 20-year patent term is from the filing date, not the grant date. Significant time can be lost during R&D and regulatory review, reducing the effective period of market exclusivity. Patent term extensions can mitigate this, but they are not guaranteed and depend on specific criteria.
- Off-Label Use of Components: While the patent covers a specific combination for a specific indication, the individual components (ALA, EPA, DHA, B vitamins) are widely available as dietary supplements. While this does not directly infringe the patent for a pharmaceutical composition and method of treatment, it creates a complex market environment.
Navigating these challenges requires a comprehensive strategy encompassing strong scientific validation, robust legal protection, strategic regulatory affairs, and effective market access initiatives. (Legal analyses of patent law, FDA regulatory pathways, pharmaceutical market access reports).
Key Takeaways
- U.S. Patent 11,752,106 protects a pharmaceutical composition combining alpha-lipoic acid, omega-3 fatty acids (EPA/DHA), and a vitamin B complex for treating neuropathic pain.
- The patent claims specifically defined compositions and methods of use, targeting conditions like diabetic neuropathy and chemotherapy-induced peripheral neuropathy.
- The claimed APIs work synergistically to address oxidative stress, inflammation, and nerve dysfunction.
- The patent landscape for neuropathic pain includes established single-agent therapies, numerous supplements, and a growing interest in combination treatments.
- Commercialization strategies may involve direct sales, licensing, or co-development, contingent on clinical success and regulatory approval.
- Potential risks include patent validity challenges, infringement litigation, regulatory hurdles, market acceptance, and limitations on exclusivity periods.
Frequently Asked Questions
1. What specific dosage ranges are protected by U.S. Patent 11,752,106?
The patent specifies preferred ranges for each active pharmaceutical ingredient, such as alpha-lipoic acid in amounts of 100 mg to 600 mg, and combined EPA and DHA in amounts of 50 mg to 500 mg, along with defined ranges for B vitamins. These ranges are detailed within the patent's claims and specification.
2. Does this patent prevent the sale of individual ALA, Omega-3, or B vitamin supplements?
No, this patent specifically covers a pharmaceutical composition containing a defined combination of these ingredients and its use in treating neuropathic pain. It does not restrict the sale of individual components as dietary supplements for general health.
3. How long is the patent protection for U.S. Patent 11,752,106 expected to last?
The patent term is typically 20 years from the filing date of the application, subject to potential adjustments for regulatory delays (Patent Term Adjustment) and extensions for certain pharmaceutical products (Patent Term Extension).
4. Can this patented composition be used for conditions other than neuropathic pain?
The patent explicitly claims its use for treating neuropathic pain and lists specific etiologies. Use for other medical conditions would require separate investigation and potentially new patent filings or licenses, provided such uses are novel and non-obvious.
5. What are the primary mechanisms by which the patented combination is intended to treat neuropathic pain?
The combination is designed to address neuropathic pain through multiple mechanisms: alpha-lipoic acid combats oxidative stress; omega-3 fatty acids reduce inflammation and support neuronal structure; and B vitamins are essential for nerve function, neurotransmitter synthesis, and myelin maintenance.
Citations
[1] United States Patent No. 11,752,106. (2023). Composition and method for treating neuropathic pain. Retrieved from USPTO database.
More… ↓
⤷ Start Trial
|
